On the Crinetics Therapeutics’ recently approved drug example we performed retroactive study with Ideation Analytics, showing how it supports patent exploration through efficient functionality and high-quality visualizations that follow medicinal chemists' workflows.

Our Biologics Solution Lead, Méliné Simsir, has compiled insights from four recent antibody conferences she has attended, bringing together perspectives from experts across the community.

During lead optimization, SAR analysis drives compound design, while patent data provides context on prior art. These perspectives are often reviewed separately, making early decisions harder. This article looks at how bringing them together in a single workflow with tools such as Discngine Ideation Analytics, reduces rework and guides more confident design choices.

Manual structure-activity relationship (SAR) reporting is a time-consuming, tedious, and repetitive task.

To regain time from data wrangling, Discngine has developed Ideation Analytics- an automated platform for SAR reporting and analysis.

To streamline the Structure-Activity Relationship (SAR) exploration of patents, it is now possible to access GOSTAR™ patent datasets directly within Ideation SAR Slides.

Structure–activity relationship (SAR) reporting is central to small-molecule drug discovery, yet many teams still rely on manual workflows. This article explores the limitations of manual SAR reporting and how they affect DMTA cycles and decision-making.

Discover how 3dpredict/Ab tackles current challenges in early antibody discovery by predicting hidden liability risks in candidates through an ensemble-based approach. By looking beyond traditional methods, it provides insights that help researchers make faster, more informed decisions on their candidates.

Discngine Meetup celebrated its fifth edition and brought together drug discovery experts to discuss recent progress and challenges in peptide discovery and design. Access event highlights and recordings.

Our scientific expert Riccardo Martini shared an extensive overview of the famous book “RNA as a drug target”, incorporating his thoughts from the modelers' and the medicinal chemists’ perspectives.